Director from uniQure Sells $135,540 of Stock in Insider Transaction

Trending News 🌥️

UNIQURE N.V ($NASDAQ:QURE) is a biotechnology company focusing on gene therapies for serious medical conditions. The company has a diversified pipeline of gene therapies in development for various diseases including hemophilia, Huntington’s disease and other rare genetic disorders. Recently, a director from UNIQURE N.V has sold $135,540 worth of stock in an insider selling transaction. Insider trading is a common practice among corporate executives, directors and other individuals with inside knowledge of a company’s operations. Insider trading can be either legal or illegal depending on the circumstances.

In the case of UNIQURE N.V, the director’s sale appears to be entirely legal and in compliance with SEC regulations. Overall, UNIQURE N.V remains a strong investment opportunity for investors interested in biotechnology stocks. With a wide range of gene therapies under development and strong financials, the company’s stock is likely to continue to perform well in the near future.

Market Price

On Monday, UNIQURE N.V stock opened at $21.9 and closed at $21.1, down by 3.5% from prior closing price of 21.9. In a recent insider transaction, the company’s director, Nessan Bermingham, sold a total of $135,540 worth of shares. This is the first insider transaction related to UNIQURE N.V that has been reported in the past six months. Insider transactions are usually considered to be important indicators for investors as they can provide information about the company’s prospects or future plans.

Insider transactions can also give valuable insight into the confidence that the company’s insiders have in its long-term prospects. It is important to keep in mind that insider transactions may not always be indicative of the company’s future performance, as there could be any number of reasons behind why Bermingham chose to sell his shares at this time. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Uniqure N.v. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Uniqure N.v. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Uniqure N.v. More…

Key Ratios Snapshot

Some of the financial key ratios for Uniqure N.v are shown below. More…

VI Analysis

Company’s fundamentals provide a great insight into its long term potential. VI app simplifies the process of analyzing a company’s fundamentals, allowing investors to make better decisions. According to VI Star Chart, UNIQURE N.V has an intermediate health score of 4/10 with regard to its cashflows and debt, indicating that the company might be able to pay off debt and fund future operations. UNIQURE N.V is strong in asset, profitability, and medium in growth, however it is weak in dividend. UNIQURE N.V is classified as an ‘elephant’, a type of company that is rich in assets after deducting off liabilities. Such companies are generally attractive to investors looking for long-term investments due to their strong balance sheets and ability to weather economic downturns. They are also attractive to value investors who seek out companies with above-average returns on equity. Furthermore, UNIQURE N.V’s strong balance sheet may also appeal to income investors seeking out companies with steady cash flows and dividends. More…

VI Peers

The competition in the gene therapy market is heating up as uniQure NV, MAIA Biotechnology Inc, Spero Therapeutics Inc, and Sio Gene Therapies Inc race to develop new treatments. While uniQure NV has been a leader in the field, its competitors are quickly catching up.

– MAIA Biotechnology Inc ($NYSEAM:MAIA)

MAIA Biotechnology Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases. MAIA Biotechnology Inc has a market cap of 41.05M as of 2022. The company has a Return on Equity of -89.15%. The company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases.

– Spero Therapeutics Inc ($NASDAQ:SPRO)

Spero Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of novel treatments for multi-drug resistant bacterial infections. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections. Spero Therapeutics Inc has a market cap of 79.08M as of 2022, a Return on Equity of -138.12%. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections.

– Sio Gene Therapies Inc ($NASDAQ:SIOX)

Sio Gene Therapies Inc. is a clinical stage gene therapy company. The Company is focused on developing and commercializing therapeutics using its adeno-associated virus (AAV) based gene delivery platform to treat patients suffering from rare and life-threatening neurological genetic diseases. Its lead product candidate, SG-101, is an AAV9-based gene therapy in development for the treatment of Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome. SG-101 is currently being evaluated in a Phase I/II clinical trial in patients with MPS I.

Summary

UniQure N.V. is a biotechnology company specializing in gene therapy products. Recently, the company’s director sold $135,540 worth of stock in an insider transaction. In response to this, the stock price of UniQure N.V. has dropped, indicating a lack of confidence in the company’s future prospects.

Investors should consider researching the company’s financials and business strategy before investing in the stock to ensure it is a good fit for their portfolio. Potential investors should also be aware of any future insider transactions as they could have an impact on the stock price.